Evgenia V. Dolgova

Institute Of Cytology And Genetics Of The Siberian Branch Of The Russian Academy Of Sciences
Novosibirsk, NVS, Russian Federation

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 18 publications

Chronometric Administration of Cyclophosphamide and a Double-Stranded DNA-Mix at Interstrand Crosslinks Repair Timing, Called "Karanahan" Therapy, Is Highly Efficient in a Weakly Immunogenic Lewis Carcinoma Model.

Chronometric Administration of Cyclophosphamide and a Double-Stranded DNA-Mix at Interstrand Crosslinks Repair Timing, Called "Karanahan" Therapy, Is Highly Efficient in a Weakly Immunogenic Lewis Carcinoma Model.

Journal: Pathology oncology research : POR

Published: November 08, 2021

Experimental Comparison of the In Vivo Efficacy of Two Novel Anticancer Therapies.

Experimental Comparison of the In Vivo Efficacy of Two Novel Anticancer Therapies.

Journal: Anticancer research

Published: May 09, 2021

Karanahan: A Potential New Treatment Option for Human Breast Cancer and Its Validation in a Clinical Setting.

Karanahan: A Potential New Treatment Option for Human Breast Cancer and Its Validation in a Clinical Setting.

Journal: Breast cancer : basic and clinical research

Published: August 26, 2020

Characterization of biological peculiarities of the radioprotective activity of double-stranded RNA isolated from Saccharomyces сerevisiae.

Characterization of biological peculiarities of the radioprotective activity of double-stranded RNA isolated from Saccharomyces сerevisiae.

Journal: International journal of radiation biology

Published: July 14, 2020

Approbation of the Cancer Treatment Approach Based on the Eradication of TAMRA+ Cancer Stem Cells in a Model of Murine Cyclophosphamide Resistant Lymphosarcoma.

Approbation of the Cancer Treatment Approach Based on the Eradication of TAMRA+ Cancer Stem Cells in a Model of Murine Cyclophosphamide Resistant Lymphosarcoma.

Journal: Anticancer research

Published: December 03, 2019

Features of monocyte-derived dendritic cells encompassing a rare subpopulation of cells that are capable of natural internalization of extracellular dsDNA.

Features of monocyte-derived dendritic cells encompassing a rare subpopulation of cells that are capable of natural internalization of extracellular dsDNA.

Journal: European cytokine network

Published: September 06, 2019

Ultrastructural analysis of the Krebs-2 ascites cancer cells treated with extracellular double-stranded DNA preparation.

Ultrastructural analysis of the Krebs-2 ascites cancer cells treated with extracellular double-stranded DNA preparation.

Journal: Ultrastructural pathology

Published: February 14, 2019

Cancer Stem Cells: Emergent Nature of Tumor Emergency.

Cancer Stem Cells: Emergent Nature of Tumor Emergency.

Journal: Frontiers in genetics

Published: July 09, 2018

Efficacy of a new cancer treatment strategy based on eradication of tumor-initiating stem cells in a mouse model of Krebs-2 solid adenocarcinoma.

Efficacy of a new cancer treatment strategy based on eradication of tumor-initiating stem cells in a mouse model of Krebs-2 solid adenocarcinoma.

Journal: Oncotarget

Published: November 01, 2017

Gene expression profiling of tumor-initiating stem cells from mouse Krebs-2 carcinoma using a novel marker of poorly differentiated cells.

Gene expression profiling of tumor-initiating stem cells from mouse Krebs-2 carcinoma using a novel marker of poorly differentiated cells.

Journal: Oncotarget

Published: August 29, 2016

Five-year disease-free survival among stage II-IV breast cancer patients receiving FAC and AC chemotherapy in phase II clinical trials of Panagen.

Five-year disease-free survival among stage II-IV breast cancer patients receiving FAC and AC chemotherapy in phase II clinical trials of Panagen.

Journal: BMC cancer

Published: June 30, 2016

Erratum to: Results of multicenter double-blind placebo-controlled phase II clinical trial of Panagen preparation to evaluate its leukostimulatory activity and formation of the adaptive immune response in patients with stage II-IV breast cancer.

Erratum to: Results of multicenter double-blind placebo-controlled phase II clinical trial of Panagen preparation to evaluate its leukostimulatory activity and formation of the adaptive immune response in patients with stage II-IV breast cancer.

Journal: BMC cancer

Published: February 11, 2016

Showing 1-12 of 18

Last Updated: 09/26/2026